2019-10 Monthly Featured Products Have Been Updated

Download PDF

2019-10 monthly featured products have been updated. BOC Sciences is a leading chemical supplier committed to providing customers with superior and high-purity featured products, which are ready to be ordered from stock.

This batch recommends 75 products containing inhibitors (agonists and antagonists), APIs, impurities, bioactive natural compounds, metabolites, carbohydrate, nucleoside, fluorescent probes, and building blocks.

45 inhibitors (agonists and antagonists) and APIs are provided in this batch. Some novel small molecules under development for clinical use are included. Here we recommend two anti-inflammatory agents, GLPG-1690 (B0084-475919) and Lifitegrast (B0084-474974), aimed at different targets and diverse indications. GLPG-1690, a selective autotaxin inhibitor developed by Galapagos, has been in a phase III clinical trial for idiopathic pulmonary fibrosis (IPF) treatment since April 2018. Autotaxin, also known as phosphodiesterase Iα/autotaxin (PD-Iα/ATX) or (ecto)nucleotide pyrophosphatase/phosphodiesterase 2 [(E)NPP2], is a multifunctional enzyme originally identified as a cell-motility-stimulating factor. It converts lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA) in lipid metabolism, promoting angiogenesis , tumor cell motility and proliferation. It is involved in some inflammatory disorders and tumors, suggesting its potential as a target for various clinical applications. Lifitegrast, under the trade name Xiidra, is a medication approved by FDA in July 2016 indicated for the treatment of keratoconjunctivitis sicca (dry eye syndrome/DED). Targeting LFA-1/ICAM-1 interaction has been demonstrated as an effective approach for DED therapeutic drug development. Lifitegrast inhibits binding of LFA-1 to ICAM-1, thus blocking T-cell migration to the inflammatory site, which is responsible for the ocular inflammatory cycle in DED. In addition to the two anti-inflammatory agents described above, more inhibitors are available in this batch.

BOC Sciences provides 7 featured impurities in this batch, containing two paclitaxel impurities 7-Troc-paclitaxel (B1473-235020) and 7-Epi-10-Desacetyl-Paclitaxel (B1473-478491). Paclitaxel is a chemotherapeutic medication used for the treatment of various cancers such as ovarian, breast caner and non-small cell lung cancer (NSCLC). It promotes microtubule polymerization and stabilization in living cells, leading to mitotic arrest in metaphase on bipolar spindles. 7-Troc-paclitaxel can be used as a precursor to paclitaxel.

For your convenience, the complete list of 2019-10 monthly featured products is available for download. If you are interested or have any questions, please feel free to contact us at info@bocsci.com.


  1. Yuelling, L. M., & Fuss, B. (2008). Autotaxin (ATX): a multi-functional and multi-modular protein possessing enzymatic lysoPLD activity and matricellular properties. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 1781(9), 525-530.
  2. Abidi, A., Shukla, P., & Ahmad, A. (2016). Lifitegrast: a novel drug for treatment of dry eye disease. Journal of pharmacology & pharmacotherapeutics, 7(4), 194.
  3. Weaver, B. A. (2014). How Taxol/paclitaxel kills cancer cells. Molecular biology of the cell, 25(18), 2677-2681.